Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
VALN
VALN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VALN News
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
17h ago
Benzinga
Latham Group Shares Surge After Strong Q4 Results
6d ago
Benzinga
Valneva Management to Attend Investor Conferences
Mar 02 2026
Newsfilter
Valneva Projects €155M–€170M Revenue for 2026
Feb 19 2026
seekingalpha
Valneva Reports 2025 Financials and 2026 Outlook
Feb 19 2026
Newsfilter
Valneva Updates Ixchiq Vaccine Recommendations in the UK
Feb 13 2026
seekingalpha
UK Updates IXCHIQ Vaccine Usage Recommendations
Feb 13 2026
Newsfilter
Valneva and Brazil Launch Pilot Chikungunya Vaccine Program
Feb 03 2026
Newsfilter
Valneva Withdraws Ixchiq Vaccine Applications Amid FDA Hold
Jan 20 2026
Benzinga
Valneva SE Withdraws Chikungunya Vaccine Applications, Shares Drop 7.7%
Jan 20 2026
Benzinga
Valneva SE Withdraws IXCHIQ Vaccine Applications Following FDA License Suspension
Jan 20 2026
NASDAQ.COM
Valneva Withdraws IXCHIQ Vaccine Applications Following FDA Suspension
Jan 19 2026
Globenewswire
Valneva to Showcase Vaccine Progress at J.P. Morgan Conference
Jan 09 2026
Globenewswire
Valneva to Showcase Vaccine Progress at J.P. Morgan Conference
Jan 09 2026
Yahoo Finance
U.S. Stocks Rise as Microchip Technology Raises Q3 Revenue Outlook to $1.185 Billion
Jan 06 2026
Benzinga
Valneva (VALN) Ends Licensing Deal with Serum Institute of India
Dec 31 2025
Yahoo Finance
Show More News
